Loading clinical trials...

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NCT01712490•Takeda

View on ClinicalTrials.gov

Summary

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Treatment-naïve participants with Ann Arbor Stage III or IV HL.
•2. Histologically confirmed classical Hodgkin Lymphoma (HL) according to the current World Health Organization (WHO) classification.
•3. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 2.
•4. Bidimensional measurable disease as documented by radiographic technique per the International Working Group Revised Criteria for Response Assessment for Malignant Lymphoma.

Exclusion Criteria

•1. Nodular lymphocyte predominant Hodgkin lymphoma.
•2. Cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (PML).
•3. Sensory or motor peripheral neuropathy.
•4. Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose.
•5. Known human immunodeficiency virus (HIV) positive.
•6. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.

Locations (215)

Birmingham, Alabama, United States

Gilbert, Arizona, United States

Tucson, Arizona, United States

Burbank, California, United States

Duarte, California, United States

Fresno, California, United States

Fullerton, California, United States

La Jolla, California, United States

Long Beach, California, United States

Los Angeles, California, United States

Key Dates

Start Date

November 9, 2012

Primary Completion Date

April 20, 2017

Completion Date

February 2, 2026

Last Updated

February 27, 2026

Enrollment

1,334

ACTUAL participants

Conditions

Hodgkin Lymphoma

Interventions

brentuximab vedotin

DRUG

doxorubicin

DRUG

bleomycin

DRUG

vinblastine

DRUG

dacarbazine

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma